The Complement Anaphylatoxin C3a Receptor (C3aR) Contributes to the Inflammatory Response in Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wende, Elisabeth ^a   Laudeley, Robert ^a   Bleich, André ^a   Bleich, Eva ^a   Wetsel, Rick A ^b   Glage, Silke ^a   Klos, Andreas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT ANAPHYLATOXIN C3A RECEPTOR; COMPLEMENT RECEPTOR; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 2; MYELOPEROXIDASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CCL 8 GENE; COLITIS; COMPLEMENT ANAPHYLATOXIN C3A RECEPTOR GENE; CONTROLLED STUDY; CXC CHEMOKINE LIGAND 9 GENE; CXCL 1 GENE; DISEASE SEVERITY; GENE; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; HISTOPATHOLOGY; MALE; MMP 3 GENE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TISSUE LEVEL; TRANSCRIPTION REGULATION; UPREGULATION; WEIGHT REDUCTION;

ACUTE DISEASE; ANIMALS; COLITIS; COLON; COMPLEMENT ACTIVATION; COMPLEMENT C3A; CYTOKINES; DEXTRAN SULFATE; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEROXIDASE; RECEPTORS, COMPLEMENT; RNA, MESSENGER;

ANIMALIA; MUS;

EID: 84876860503     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062257     Document Type: Article

References (38)

1. Sandborn WJ, Faubion WA, (2004) Biologics in inflammatory bowel disease: how much progress have we made? Gut 53: 1366-73.
2. Perrier C, Rutgeerts P, (2011) Cytokine blockade in inflammatory bowel diseases. Immunotherapy. 3: 1341-52.
3. Klos A, Wende E, Wareham KJ, Monk PN, (2013) International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors. Pharmacol Rev 65: 500-43.
4. Heeger PS, Kemper C, (2012) Novel roles of complement in T effector cell regulation. Immunobiology 217: 216-24.
5. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA, (2002) Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 169: 5926-33.
6. Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, et al. (2010) Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol 11: 928-35.
7. Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P, (1992) Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut 33: 902-8.
8. Ueki T, Mizuno M, Uesu T, Kiso T, Nasu J, et al. (1996) Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 104: 286-92.
9. Scheinin T, Bohling T, Halme L, Kontiainen S, Bjorge L, et al. (1999) Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease. Hum Pathol 30: 1427-30.
10. Deguchi Y, Andoh A, Inatomi O, Araki Y, Hata K, et al. (2005) Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med 16: 605-8.
11. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME, (2004) Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 172: 3836-41.
12. Johswich K, Martin M, Bleich A, Kracht M, Dittrich-Breiholz O, et al. (2009) Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis 15: 1812-23.
13. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, et al. (2003) A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 171: 5514-20.
14. Woodruff TM, Pollitt S, Proctor LM, Stocks SZ, Manthey HD, et al. (2005) Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther 314: 811-7.
15. Chen G, Yang Y, Gao X, Dou Y, Wang H, et al. (2010) Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab Invest 91(3): 472-83.
16. Nicklas W, Deeny A, Diercks P, Gobbi A, Illgen-Wilcke B, et al. (2010) FELASA guidelines for the accreditation of health monitoring programs and testing laboratories involved in health monitoring. Lab Anim (NY) 39: 43-8.
17. Cooper HS, Murthy SN, Shah RS, Sedergran DJ, (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-49.
18. Bleich A, Mahler M, Most C, Leiter EH, Liebler-Tenorio E, et al. (2004) Refined histopathologic scoring system improves power to detect colitis QTL in mice. Mamm Genome 15: 865-71.
19. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, et al. (2001) Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 281: R1264-R1273.
20. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, et al. (2009) Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 296: G1140-G1149.
21. Banks C, Bateman A, Payne R, Johnson P, Sheron N, (2003) Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 199: 28-35.
22. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S, (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47: 63-73.
23. Kobayashi K, Arimura Y, Goto A, Okahara S, Endo T, et al. (2006) Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. J Pathol 209: 376-83.
24. Park MK, Amichay D, Love P, Wick E, Liao F, et al. (2002) The CXC chemokine murine monokine induced by IFN-gamma (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. J Immunol 169: 1433-43.
25. Bouma G, Strober W, (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-33.
26. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, et al. (1994) Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-52.
27. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114: 385-91.
28. Qualls JE, Kaplan AM, Van Rooijen N, Cohen DA, (2006) Suppression of experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol 80: 802-15.
29. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, et al. (2009) Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 15: 341-52.
30. Myers KJ, Murthy S, Flanigan A, Witchell DR, Butler M, et al. (2003) Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther 304: 411-24.
31. Naito Y, Takagi T, Handa O, Ishikawa T, Nakagawa S, et al. (2003) Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 18: 560-9.
32. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, et al. (2000) Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 62: 240-8.
33. Shea-Donohue T, Thomas K, Cody MJ, Aiping Z, Detolla LJ, et al. (2008) Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun 14: 117-24.
34. Zenewicz LA, Antov A, Flavell RA, (2009) CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 15: 199-207.
35. Strainic MG, Liu J, Huang D, An F, Lalli PN, et al. (2008) Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28: 425-35.
36. Strainic MG, Shevach EM, An F, Lin F, Medof ME, (2012) Absence of signaling into CD4(+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3(+) regulatory T cells. Nat Immunol 14: 162-71.
37. Melgar S, Karlsson A, Michaelsson E, (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288: G1328-G1338.
38. Mahler M, Bristol IJ, Leiter EH, Workman AE, Birkenmeier EH, et al. (1998) Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 274: G544-G551.